New vaccine aims to tame hepatitis b in patients on antivirals
NCT ID NCT03866187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new therapeutic vaccine (GSK3528869A) in adults aged 18-65 with chronic hepatitis B whose virus was already well-controlled by standard antiviral pills. The goal was to see if the vaccine could safely lower hepatitis B surface antigen levels and possibly allow patients to stop long-term medication. The study was terminated early, so final results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Antwerp, 2650, Belgium
-
GSK Investigational Site
Brussels, 1000, Belgium
-
GSK Investigational Site
Brussels, 1070, Belgium
-
GSK Investigational Site
Edegem, 2650, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Clichy, 92118, France
-
GSK Investigational Site
Créteil, 94010, France
-
GSK Investigational Site
Lyon, 69317, France
-
GSK Investigational Site
Strasbourg, 67091, France
-
GSK Investigational Site
Berlin, 10787, Germany
-
GSK Investigational Site
Bonn, 53127, Germany
-
GSK Investigational Site
Essen, 45122, Germany
-
GSK Investigational Site
Frankfurt, 60590, Germany
-
GSK Investigational Site
Hamburg, 20246, Germany
-
GSK Investigational Site
Mainz, 55131, Germany
-
GSK Investigational Site
Pokfulam, Hong Kong
-
GSK Investigational Site
Krakow, 31-202, Poland
-
GSK Investigational Site
Mysłowice, 41-400, Poland
-
GSK Investigational Site
Poznan, 60-185, Poland
-
GSK Investigational Site
Łańcut, 37-100, Poland
-
GSK Investigational Site
Barcelona, 08011, Spain
-
GSK Investigational Site
Barcelona, 08907, Spain
-
GSK Investigational Site
Córdoba, 14004, Spain
-
GSK Investigational Site
Granada, 18016, Spain
-
GSK Investigational Site
Madrid, 28006, Spain
-
GSK Investigational Site
Madrid, 28007, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Madrid, 28222, Spain
-
GSK Investigational Site
Palma de Mallorca, 07120, Spain
-
GSK Investigational Site
Santander, 39008, Spain
-
GSK Investigational Site
Seville, 41013, Spain
-
GSK Investigational Site
TorrejOn Ardoz Madrid, 28850, Spain
-
GSK Investigational Site
Taichung, 40447, Taiwan
-
GSK Investigational Site
Taichung, 40705, Taiwan
-
GSK Investigational Site
Tainan, 704, Taiwan
-
GSK Investigational Site
Taipei, 112, Taiwan
-
GSK Investigational Site
Taoyuan, 333, Taiwan
-
GSK Investigational Site
Bangkok, 10330, Thailand
-
GSK Investigational Site
Chiang Mai, 50200, Thailand
-
GSK Investigational Site
London, E1 1BB, United Kingdom
-
GSK Investigational Site
London, SW17 0QT, United Kingdom
-
GSK Investigational Site
Nottingham, NG7 2UH, United Kingdom